共 94 条
[1]
Jolles S(2005)Clinical uses of intravenous immunoglobulin Clin Exp Immunol 142 1-11
[2]
Sewell WA(2011)Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation Immunol Res 51 61-70
[3]
Misbah SA(1952)Agammaglobulinemia Pediatrics 9 722-8
[4]
Modell V(2012)Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again J Clin Immunol 32 1153-64
[5]
Gee B(2011)Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach Adv Ther 28 521-33
[6]
Lewis DB(2000)The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 94-100
[7]
Orange JS(2004)Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home J Allergy Clin Immunol 114 936-42
[8]
Roifman CM(2006)Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home J Clin Immunol 26 65-72
[9]
Routes JM(2013)Why I, use subcutaneous immunoglobulin (SCIG) J Clin Immunol 33 S95-8
[10]
Bruton OC(2009)Pharmacoeconomics of immunoglobulins in primary immunodeficiency Expert Rev Pharmacoecon Outcomes Res 9 375-86